Octapharma USA recently announced a new co-pay assistance program for individuals who receive Wilate® or for those who have a prescription to begin therapy. Wilate®, Octapharma’s plasma-derived von Willebrand factor/factor VIII product, is indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD). It is also for patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.
The program offers eligible patients a maximum of $6,000 annually for co-pay, co-insurance and deductible expenses associated with their treatment without regard for their ability to pay. Patients must have third-party commercial insurance to participate in the program.
“We realize that patient out-of-pocket expenses associated with healthcare can sometimes be daunting, therefore, Octapharma has committed to support a program specifically designed to supplement these costs,” said Octapharma USA President Flemming Nielsen. “Octapharma is focused on creating support programs that adapt to meet patient needs and ensure continued access to therapies recommended by their medical providers. Coupled with ongoing educational programs, these efforts emphasize our strong belief that patient needs must always come first.”
To enroll in the Octapharma Co-Pay Assistance Program, eligible patients should contact the Octapharma Support Center: 800.554.4440. The program is not available to patients who are covered under Medicaid, Medicare, MediGap, VA, DOD, TRICARE or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program. Participants must be residents of the US.
Source: Octapharma press release dated January 27, 2015
